Overview of clinical data for candesartan pdf

Clinical trials of candesartan and the meta-analysis of their results are available for the following clinical conditions:

atrial fibrillation

patient with history of atrial fibrillation (in overview of all prevention) pdf

candesartan vs placebo : CAPRAF (Tveit) ,2007 -

patients without history of AF (primary prevention) (in overview of all prevention) pdf

candesartan vs placebo : CHARM (AF ancillary study) ,2005 -

heart failure

all type of patients (in overview of all angiotensin-receptor blockers) pdf

candesartan vs enalapril : RESOLVD (candesartan alone) ,1999 -
candesartan vs placebo : ARCH-J ,2003 - CHARM-Alternative ,2003 - Mitrovic et al. ,2003 - SPICE ,2000 - STRETCH ,1999 -
candesartan+ACE inhibitor vs ACE inhibitor only : CHARM-Added ,2003 - RESOLVD association ,1999 -

patients already receiving ACE inhibitor (in overview of all angiotensin-receptor blockers) pdf

candesartan+ACE inhibitor vs ACE inhibitor only : CHARM-Added ,2003 -

patients intolerant to ACE inhibitors (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : CHARM-Alternative ,2003 - SPICE ,2000 -

patients previously untreated with ACE inhibitors (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : ARCH-J ,2003 -

patients with preserved-LVEF heart failure (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : CHARM preserved ,2003 -

patients with preserved-LVEF heart failure (in overview of all inhibition of the renin-angiotensin system (ACEI or ARB)) pdf

candesartan vs placebo : CHARM preserved ,2003 -

heart failure with preserved LVEF

all type of patients (in overview of all All mecanism) pdf

candesartan vs placebo : CHARM preserved ,2003 -

hypertension

all diseases requiring ACEi (HF, CHD, HT,...) (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : SCOPE ,2003 -
Candesartan vs usual care : HIJ-CREATE ,2009 -

all type of patient (in overview of all anti hypertensive agent) pdf

candesartan vs placebo : SCOPE ,2003 -

patients undergoing dialysis (in overview of all anti hypertensive agent) pdf

candesartan vs usual care : Takahashi et al ,2006 - Suzuki et al ,2008 -

subjects with pre-hypertension (in overview of all anti hypertensive agent) pdf

candesartan vs placebo : TROPHY ,2006 -

miscellaneous

all type of patients (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : SCOPE ,2003 - TROPHY ,2006 -

patients at high risk for cardiovascular events

all type of patients (in overview of all angiotensin-receptor blockers) pdf

candesartan vs placebo : SCOPE ,2003 -

Entry terms: 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate, candesartan cilexetil, 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate, TCV 116, TCV-116, Atacand, Astra brand of candesartan cilexetil, Takeda brand of candesartan cilexetil, Blopress, Kenzen, Promed brand of candesartan cilexetil, Amias, AstraZeneca brand of candesartan cilexetil, Parapres, Almirall brand of candesartan cilexetil, candesartan, 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole, CV 11974, CV11974, CV-11974